Patient-friendly, non-technical summary of research papers

February 2026 Research Update

This report covers research on Splenic marginal zone lymphoma published in PubMed in February 2026. For other months, see all research updates.

Last update: September 2, 2026

At a glance

Spleen rupture

SMZL may first be found after a sudden spleen rupture.

Warm autoimmune anemia

Severe immune red-cell breakdown may be the first sign.

Abdominal fluid testing

Abdominal fluid tests may miss lymphoma even when present.

R-CVP remission

One reported patient had complete remission after R-CVP.

Unusual first signs

This month highlighted uncommon first symptoms in SMZL from three single-patient reports. Diagnosis sometimes relied on spleen or bone marrow tissue when fluid tests were unclear.

Overview

This month focused on unusual first signs of splenic marginal zone lymphoma (SMZL). The new papers were three single-patient reports. They mainly add awareness of how diagnosis can start from unexpected problems.

One report described SMZL being found only after an emergency spleen rupture without injury. In that situation, removing the spleen was part of urgent care. The removed spleen also provided the tissue needed to confirm SMZL.

Another report linked an SMZL-like lymphoma with severe warm autoimmune hemolytic anemia, which is when the immune system breaks down red blood cells. That case also reported genetic findings like MYD88 L265P and MYC copy-number gain. The report could not confirm SMZL from spleen tissue.

A third report connected SMZL with chylous ascites, which is persistent milky fluid in the abdomen, lasting 3 years. In that case, imaging and a bone marrow biopsy supported SMZL without splenectomy. Testing of the abdominal fluid did not show clear lymphoma cells, even though SMZL was present.

Get the monthly update by email

Subscribe here to receive an email when a new monthly splenic marginal zone lymphoma update is published. You can unsubscribe at any time. Your address is used for this only; delivery is handled by MailerLite (privacy policy).

Research topics this month

This month, the new reports did not change what is known about typical splenic marginal zone lymphoma, but they made it clearer how differently it can first appear in real life. Across three single-patient reports, SMZL or an SMZL-like lymphoma first showed up as an emergency spleen bleed, severe autoimmune breakdown of red blood cells, or persistent milky abdominal fluid (chylous ascites).

One report showed that SMZL can be discovered only after an unexpected, non-injury-related splenic rupture, where urgent procedures were needed to stop bleeding and remove the spleen. In that situation, examining the removed spleen provided the tissue needed to confirm SMZL.

Another report described an SMZL-suspicious small B-cell lymphoma that presented mainly through severe warm autoimmune hemolytic anemia, along with a very enlarged spleen. Genetic testing in that case found changes such as MYD88 L265P and MYC copy-number gain, which the authors discussed as potentially important for understanding a higher-risk biology, although the report could not confirm SMZL from splenic tissue.

A third report connected SMZL with years of refractory chylous ascites, where the diagnosis was made using imaging and a bone marrow biopsy rather than a splenectomy. In that patient, testing of the abdominal fluid did not show a clear lymphoma B-cell population, but the marrow findings supported SMZL, showing that fluid tests can be non-diagnostic even when lymphoma is present.

For patients and caregivers, the main message is that SMZL can sometimes be recognized only after a very unexpected problem, and the first clue may not look like a typical lymphoma story. These are case reports, so they cannot tell how often these presentations happen, but they help explain why diagnosis can take time when symptoms come from bleeding, autoimmune anemia, or chronic abdominal fluid buildup.

This month also adds a practical point about diagnosis: different paths may be used to reach an SMZL diagnosis, including spleen tissue after splenectomy in an emergency, or bone marrow and imaging when splenectomy is avoided. It remains uncertain how broadly the genetic findings and short follow-up from a single patient apply to others, but the report shows the kinds of extra testing that may be used when the diagnosis is not straightforward.

Limitations

All findings came from three single-patient reports, so they cannot show how common these presentations are.
Some conclusions relied on limited tissue confirmation, including one SMZL-like case without spleen tissue proof.
Genetic findings and treatment response were described in single cases, so it is unclear how broadly they apply.

Important information

This document summarizes recent research from PubMed-indexed publications using automated methods.
It is intended for educational purposes and does not replace medical advice.
Links to the original studies are provided via PubMed, where readers can explore abstracts and, when available, access full-text articles.
Some studies may include additional details that were not accessible for this summary.
Readers seeking more complete detail or context may find it helpful to review the original studies directly.